1. Chang KY, Chang JY, Yen Y. Increasing incidence of intrahepatic cholangiocarcinoma and its relationship to chronic viral hepatitis. J Natl Compr Canc Netw. 2009;7(4):423-427. doi:10.6004/jnccn. 2009.0030
2. Amini N, Ejaz A, Spolverato G, Kim Y, Herman JM, Pawlik TM. Temporal trends in liver-directed therapy of patients with intrahepatic cholangiocarcinoma in the United States:a population-based analysis. J Surg Oncol. 2014;110 (2):163-170. doi:10.1002/jso.23605
3. Mavros MN, Economopoulos KP, Alexiou VG, Pawlik TM. Treatment and prognosis for patients with intrahepatic cholangiocarcinoma: systematic review and meta-analysis. JAMA Surg. 2014;149(6): 565-574. doi:10.1001/jamasurg.2013.5137
4. Kim DH, Choi DW, Choi SH, Heo JS, Kow AW. Is there a role for systematic hepatic pedicle lymphadenectomy in intrahepatic cholangiocarcinoma? a review of 17 years of experience in a tertiary institution. Surgery. 2015; 157(4):666-675. doi:10.1016/j.surg.2014.11.006
5. Zhang XF, Beal EW, Bagante F, et al. Early versus late recurrence of intrahepatic cholangiocarcinoma after resection with curative intent. Br J Surg. 2018; 105(7):848-856. doi:10.1002/bjs.10676
6. Doussot A, Gonen M, Wiggers JK, et al. Recurrence patterns and disease-free survival after resection of intrahepatic cholangiocarcinoma: preoperative and postoperative prognostic models. J Am Coll Surg. 2016;223(3):493-505.e2. doi:10.1016/j.jamcollsurg.2016.05.019
7. Wang C, Pang S, Si-Ma H, et al. Specific risk factors contributing to early and late recurrences of intrahepatic cholangiocarcinoma after curative resection. World J Surg Oncol. 2019;17(1):2. doi:10.1186/s12957-018-1540-1
8. Tsilimigras DI, Sahara K, Moris D, et al. Effect of surgical margin width on patterns of recurrence among patients undergoing R0 hepatectomy for T1 hepatocellular carcinoma: an international multi-institutional analysis. J Gastrointest Surg. 2019. doi:10.1007/s11605-019-04275-0
9. Xu XF, Xing H, Han J, et al. Risk factors, patterns, and outcomes of late recurrence after liver resection for hepatocellular carcinoma: a multicenter study from China. JAMA Surg. 2019; 154(3):209-217. doi:10.1001/jamasurg.2018.4334
10. Tsilimigras DI, Hyer JM, Moris D, et al; International Intrahepatic Cholangiocarcinoma Study Group. Prognostic utility of albumin-bilirubin grade for short- and long-term outcomes following hepatic resection for intrahepatic cholangiocarcinoma: a multi-institutional analysis of 706 patients. J Surg Oncol. 2019;120(2):206-213. doi:10.1002/jso.25486
11. Tsilimigras DI, Mehta R, Moris D, et al. A machine-based approach to preoperatively identify patients with the most and least benefit associated with resection for intrahepatic cholangiocarcinoma: an international multi-institutional analysis of 1,146 patients. Ann Surg Oncol. 2020;27(4):1110-1119. doi:10.1245/s10434-019-08067-3
12. Tsilimigras DI, Mehta R, Aldrighetti L, et al; International Intrahepatic Cholangiocarcinoma Study Group. Development and validation of a laboratory risk score (LabScore) to predict outcomes after resection for intrahepatic cholangiocarcinoma. J Am Coll Surg. 2020;230(4): 381-391.e2. doi:10.1016/j.jamcollsurg.2019.12.025
13. Simon R, Sasaki K, Margonis GA, et al. Risk factors for very early recurrence of hepatocellular carcinoma: a retrospective review. HPB (Oxford). 2018;20:2. doi:10.1016/j.hpb.2018.02.327
14. Hirokawa F, Hayashi M, Asakuma M, Shimizu T, Inoue Y, Uchiyama K. Risk factors and patterns of early recurrence after curative hepatectomy for hepatocellular carcinoma. Surg Oncol. 2016;25(1): 24-29. doi:10.1016/j.suronc.2015.12.002
15. Jung SW, Kim DS, Yu YD, Han JH, Suh SO. Risk factors for cancer recurrence or death within 6 months after liver resection in patients with colorectal cancer liver metastasis. Ann Surg Treat Res. 2016;90(5):257-264. doi:10.4174/astr.2016.90.5.257
16. Takahashi S, Konishi M, Nakagohri T, Gotohda N, Saito N, Kinoshita T. Short time to recurrence after hepatic resection correlates with poor prognosis in colorectal hepatic metastasis. Jpn J Clin Oncol. 2006;36(6):368-375. doi:10.1093/jjco/hyl027
17. Strasberg SM. Nomenclature of hepatic anatomy and resections: a review of the Brisbane 2000 system. J Hepatobiliary Pancreat Surg. 2005; 12(5):351-355. doi:10.1007/s00534-005-0999-7
18. Amin MB, Greene FL, Edge SB, et al. The Eighth Edition AJCC Cancer Staging Manual: continuing to build a bridge from a population-based to a more “personalized” approach to cancer staging. CA Cancer J Clin. 2017;67(2):93-99. doi:10.3322/caac. 21388
19. Hu LS, Zhang XF, Weiss M, et al. Recurrence patterns and timing courses following curative-intent resection for intrahepatic cholangiocarcinoma. Ann Surg Oncol. 2019;26(8): 2549-2557. doi:10.1245/s10434-019-07353-4
20. Lee KJ, Carlin JB. Multiple imputation for missing data: fully conditional specification versus multivariate normal imputation. Am J Epidemiol. 2010;171(5):624-632. doi:10.1093/aje/kwp425
21. Camp RL, Dolled-Filhart M, Rimm DL. X-tile: a new bio-informatics tool for biomarker assessment and outcome-based cut-point optimization. Clin Cancer Res. 2004;10(21):7252- 7259. doi:10.1158/1078-0432.CCR-04-0713
22. Facciabene A, Peng X, Hagemann IS, et al. Tumour hypoxia promotes tolerance and angiogenesis via CCL28 and T(reg) cells. Nature. 2011;475(7355):226-230. doi:10.1038/nature10169
23. Chan AWH, Zhong J, Berhane S, et al. Development of pre and post-operative models to predict early recurrence of hepatocellular carcinoma after surgical resection. J Hepatol. 2018; 69(6):1284-1293. doi:10.1016/j.jhep.2018.08.027
24. Margonis GA, Sasaki K, Gholami S, et al. Genetic And Morphological Evaluation (GAME) score for patients with colorectal liver metastases. Br J Surg. 2018;105(9):1210-1220. doi:10.1002/bjs.10838
25. Valle J, Wasan H, Palmer DH, et al; ABC-02 Trial Investigators. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med. 2010;362(14):1273-1281. doi:10.1056/ NEJMoa0908721
26. Bagante F, Spolverato G, Merath K, et al. Intrahepatic cholangiocarcinoma tumor burden: a classification and regression tree model to define prognostic groups after resection. Surgery. 2019; 166(6):983-990. doi:10.1016/j.surg.2019.06.005
27. Sahara K, Tsilimigras DI, Mehta R, et al. A novel online prognostic tool to predict long-term survival after liver resection for intrahepatic cholangiocarcinoma: the “metro-ticket” paradigm. J Surg Oncol. 2019;120(2):223-230. doi:10.1002/jso. 25480
28. Yeh CN, Jan YY, Chen MF. Influence of age on surgical treatment of peripheral cholangiocar- cinoma. Am J Surg. 2004;187(4):559-563.doi:10.1016/j.amjsurg.2003.12.051
29. Beheshti A, Benzekry S, McDonald JT, et al. Host age is a systemic regulator of gene expression impacting cancer progression. Cancer Res. 2015;75 (6):1134-1143. doi:10.1158/0008-5472.CAN-14-1053
30. Kleeff J, Reiser C, Hinz U, et al. Surgery for recurrent pancreatic ductal adenocarcinoma. Ann Surg. 2007;245(4):566-572. doi:10.1097/01.sla. 0000245845.06772.7d
31. Youngwirth LM, Nussbaum DP, Thomas S, et al. Nationwide trends and outcomes associated with neoadjuvant therapy in pancreatic cancer: an analysis of 18 243 patients. J Surg Oncol. 2017;116(2):127-132. doi:10.1002/jso.24630
32. Heinrich S, Schäfer M, Weber A, et al. Neoadjuvant chemotherapy generates a significant tumor response in resectable pancreatic cancer without increasing morbidity: results of a prospective phase II trial. Ann Surg. 2008;248(6): 1014-1022. doi:10.1097/SLA.0b013e318190a6da
33. Leonard GD, Brenner B, Kemeny NE. Neoadjuvant chemotherapy before liver resection for patients with unresectable liver metastases from colorectal carcinoma. J Clin Oncol. 2005;23 (9):2038-2048. doi:10.1200/JCO.2005.00.349
34. Greer SE, Pipas JM, Sutton JE, et al. Effect of neoadjuvant therapy on local recurrence after resection of pancreatic adenocarcinoma. J Am Coll Surg. 2008;206(3):451-457. doi:10.1016/j.jamcollsurg.2007.10.002
35. Darwish Murad S, Kim WR, Harnois DM, et al. Efficacy of neoadjuvant chemoradiation, followed by liver transplantation, for perihilar cholangiocarcinoma at 12 US centers. Gastroenterology. 2012;143(1):88-98.e3. doi:10.1053/ j.gastro.2012.04.008
36. Buettner S, Koerkamp BG, Ejaz A, et al. The effect of preoperative chemotherapy treatment in surgically treated intrahepatic cholangiocarcinoma patients—a multi-institutional analysis. J Surg Oncol. 2017;115(3):312-318. doi:10.1002/jso.24524
37. Borad MJ, Champion MD, Egan JB, et al. Integrated genomic characterization reveals novel, therapeutically relevant drug targets in FGFR and EGFR pathways in sporadic intrahepatic cholangiocarcinoma. PLoS Genet. 2014;10(2): e1004135. doi:10.1371/journal.pgen.1004135
38. Farshidfar F, Zheng S, Gingras M-C, et al; Cancer Genome Atlas Network. Integrative genomic analysis of cholangiocarcinoma identifies distinct IDH-mutant molecular profiles. Cell Rep. 2017;18 (11):2780-2794. doi:10.1016/j.celrep.2017.02.033